tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

OCX Stock Latest News

Oncocyte Reports First Quarter 2023 Financial Results
Press ReleasesOncocyte Reports First Quarter 2023 Financial Results
27d ago
OCX
Oncocyte Presents New Data at AACR
Press ReleasesOncocyte Presents New Data at AACR
2M ago
OCX
Oncocyte Announces Reduction in Force
Press ReleasesOncocyte Announces Reduction in Force
2M ago
OCX
OncoCyte reduces workforce by approximately 20%
The FlyOncoCyte reduces workforce by approximately 20%
2M ago
OCX
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
Press ReleasesOncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
2M ago
OCX
OncoCyte announces peer-reviewed publication of DetermaIO study
The FlyOncoCyte announces peer-reviewed publication of DetermaIO study
2M ago
OCX
OncoCyte price target lowered to $0.45 from $1.40 at Needham
The FlyOncoCyte price target lowered to $0.45 from $1.40 at Needham
2M ago
OCX
OncoCyte prices $13.9M common stock offering
The FlyOncoCyte prices $13.9M common stock offering
2M ago
OCX
OncoCyte Corp (OCX) Q4 Earnings Cheat Sheet
Pre-EarningsOncoCyte Corp (OCX) Q4 Earnings Cheat Sheet
2M ago
OCX
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
Press ReleasesOncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
2M ago
OCX
OncoCyte to delay filing Annual Report on Form 10-K
The FlyOncoCyte to delay filing Annual Report on Form 10-K
2M ago
OCX
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
Press ReleasesOncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
2M ago
OCX
OncoCyte Corp (OCX) Q4 Earnings Cheat Sheet
Pre-EarningsOncoCyte Corp (OCX) Q4 Earnings Cheat Sheet
2M ago
OCX
Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
Press ReleasesOncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
3M ago
OCX
OncoCyte appoints Riggs as President, CEO
The FlyOncoCyte appoints Riggs as President, CEO
3M ago
OCX
OncoCyte completes Razor Genomics transaction
The FlyOncoCyte completes Razor Genomics transaction
4M ago
OCX
Oncocyte Completes Razor Genomics Transaction
Press ReleasesOncocyte Completes Razor Genomics Transaction
4M ago
OCX
Oncocyte to eliminate president, COO, CSO positions
The FlyOncocyte to eliminate president, COO, CSO positions
6M ago
OCX
Oncocyte Announces Initiatives to Focus Corporate Strategy
Press ReleasesOncocyte Announces Initiatives to Focus Corporate Strategy
6M ago
OCX
Oncocyte reduces workforce by 40%, agrees to transfer 70% ownership in Razor
The FlyOncocyte reduces workforce by 40%, agrees to transfer 70% ownership in Razor
6M ago
OCX
OncoCyte downgraded to Hold from Buy at Lake Street
The FlyOncoCyte downgraded to Hold from Buy at Lake Street
6M ago
OCX
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
Press ReleasesOncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
6M ago
OCX
iosandroid
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterETF Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksCareersContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.